1 | PromarkerD | Yes | Commercialization | DKD | Waiting for Ph2 from Janssen to determine disease regression from Invokana & CVD indication. Awaiting 513g to submit either 510k or DeNovo FDA submission. Awaiting CPT code for reimbursement. |
|
---|
2 | Endometriosis | Yes | Pending Validation study | Identified and filed a patent for novel biomarkers which could be used to develop a blood test to detect Endometriosis.
Proof of concept study performed on 54 women returned statistically significant results | Q4-20 - Waiting on access to blood bank to perform validation study. | Keep up to date with DOTENDO, note DotEndo started their clinical trial already with x750 patients but trail end date is 2024.. long study. |
---|
3 | Giardia | Yes | Validation study results under analysis | Giardia is a leading cause of infectious gastroenteritis worldwide and one of the most common parasitic human diseases. | Q1-21 -Identified strain specific Giardia targets and developed a prototype immunoassay, pending validation using field samples. | Collaboration with the Murdoch University Veterinary School and a leading US veterinary company. |
---|
4 | Asthma & COPD | Yes | Results from Proof-of-Concept study under analysis. | The study is in collaboration with the Busselton Population Medical Research Institute, which gives Proteomics International access to the globally-recognised Busselton Health Study, first established in 1966 and one of the longest running epidemiological research programs in the world. | Q1-21 - Waiting on results from Proof of Concept study. | DMX 700 (DXB) also working on COPD. Will there be any future collab similar to the DKD collab that was meant to happen. |
---|
5 | Plant dieback | Yes | Results from Discovery study under analysis | Collaboration with the Centre for Crop and Disease Management (Curtin University) to target the plant pathogen Phytophthora cinnamomi, which is responsible for plant dieback that affects a wide variety of native plant species and premium crops such as avocados and macadamias. Current investigations are focused on proteomic analysis (determining the protein maps) of the life stages of the organism and how it infects its host. This may lead to a field test for the easier detection of infected soil, and has the potential to identify weaknesses in the pathogen that could be targeted to help eradicate this disease. | Q1-21: Waiting on results from discovery study | What's the addressable market for this? How is this managed today? Need to do more research.. |
---|
6 | Diabetic retinopathy | No | Discovery study ongoing | Following the success of its diabetic kidney disease project, Proteomics International signed a new collaboration agreement with The University of Western Australia to seek early markers for diabetic retinopathy, the major cause of blindness in the US. This collaboration is applying the Promarker TM platform to look for prognostic markers in the blood that can identify patients at risk of retinopathy, especially sight-threatening retinopathy. The program will again utilise the Fremantle Diabetes Study which provided the rich sample repository that led to PromarkerD. | Q1-21: In Discovery |
|
---|
7 | Oxidative stress (2-tag) | Yes | Validation studies pending; Commercialisation discussions underway. | Collaboration with The University of Western Australia to develop methodology that could become the next generation of medical diagnostic tests. The patented technology called "2-tag" measures the oxidative stress in a system. | Q4-20: In commercial discussions | *Need to read more into what this is and clinical use cases |
---|
8 | Oesophageal cancer | No | Technology transfer ongoing; Clinical Validation pending. | Proteomics International has joined forces with QIMR Berghofer Medical Research Institute to improve detection of oesophageal adenocarcinoma, the most common form of oesophageal cancer in Australia. Proteomics International is employing its Promarker TM platform to analytically and then clinically validate a panel of biomarkers - protein ‘fingerprints’ in the blood - that QIMR Berghofer researchers found are associated with early stages of the cancer. The aim is to develop a simple blood test for oesophageal adenocarcinoma. | Q4-20: Technology transfer ongoing; Clinical Validation pending. | Collab agreement was only for 1 year, expires Oct, 2021 |
---|
9 | COVID19 |
| Suspended |
| Q1-21: The development studies were completed, however, the research programs have been suspended in light of the extensive resources directed at COVID-19 worldwide |
|
---|
10 | OCProDx |
| Dead? | No news since first announced, assume study has been cancelled. |
|
|
---|